Cronos Group Inc. (CRON) - Stock Analysis

Last updated: Mar 7, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Cronos Group shows record revenue and profitability growth, an accretive European acquisition, strong liquidity, and a 33% 3-week stock surge breaking resistance, backed by favorable regulatory outlook and cannabis sector tailwinds, making it a highly attractive short-term growth idea.

Loading chart data...

Idea window: 12/15/2025 – 12/22/2025Sector: Healthcare

AI Analyst Overview

Last Price
$2.50
Market Cap
$961.55M
1D Return
+0.40%
YTD Return
-4.94%

Loading chart data...

Valuation Metrics

P/E
-101.9
P/B
0.9
P/S
6.5
EV/EBITDA
29.6
Div Yield
—

Fundamental Analysis

6.0

Key Financial Insights: • Exceptional liquidity • Low leverage • Persistent losses Cronos Group is cash-rich with extremely low leverage and healthy gross margins but suffers persistent operating losses and weak free cash flow, leaving it conservatively capitalized yet operationally challenged.

liquidity
profitability

Price Behavior

5.0

Key Price Behavior Insights: • Below SMA • Tight range • Neutral momentum Support Level: $2.56 Resistance Level: $2.77 CRON is mildly bearish over the last month—closing below its last month SMA with a neutral RSI and trading tightly between $2.56 and $2.77, vulnerable to further downside if $2.56 breaks.

weak
range

Sentiment & News

6.0

Key News Insights: • Revenue surge • Geographic expansion • Capacity growth Cronos reported a record 2025 with full-year revenue +25% (Q4 +47%), driven by strong Canadian demand, international expansion (Israel, Europe, Australia), capacity increases (GrowCo +70% flower volume) and M&A, boosting margins and investor interest.

growth
expansion
AI

AI Summary

6.0
Neutral

With cash and short-term investments nearly equal to market cap, Cronos has shifted from a survival story to a liquidity-backed execution play—its ability to convert GrowCo's capacity ramp, international premiumization and CanAdelaar M&A into durable margin expansion and positive free cash flow within 12–24 months is the decisive catalyst, while prolonged negative FCF, GrowCo underperformance or costly integration would quickly erode that optionality.

CashRunway
ExecutionRisk
International
AI summary updated 7 days ago

Description

Cronos Group Inc. is a Toronto-based cannabinoid company that develops, manufactures and sells hemp-derived supplements and cosmetics through e-commerce, retail and hospitality partners under the Lord Jones and Happy Dance brands. The company also cultivates and produces cannabis for medical and adult-use markets, marketing a range of consumer products through wholesale and direct channels via its PEACE NATURALS wellness platform and adult-use brands such as Spinach, and exports cannabis goods to Germany, Israel and Australia. Founded in 2012, Cronos operates across both domestic and international markets.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Dec 15Dec 22CRONCronos Group Inc.
Cronos Group shows record revenue and profitability growth, an accretive European acquisition, strong liquidity, and a 33% 3-week stock surge breaking resistance, backed by favorable regulatory outlook and cannabis sector tailwinds, making it a highly attractive short-term growth idea.
Closed-8.8%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.